newsfilter
← Earnings
Earnings Releases·

Viridian Therapeutics — Third Quarter 2026 Earnings Summary

  • Total revenues declined to $25.8 million from $70.6 million year-over-year due to a drop in license revenue, though net product revenue from Lumvoa reached $24.7 million compared to $0 in the prior year period.
  • Net loss widened to $101.2 million from $34.6 million, driven by increased SG&A expenses of $57.6 million to support commercial activities, partially offset by a reduction in R&D expenses to $70.1 million.
  • The company expects to submit a BLA for elegrobart in Q1 2027 and initiate Phase 1 trials for VRDN-292 in Q4 2026, with existing cash reserves of $955.2 million projected to fund operations through profitability.
  • Lumvoa achieved significant market access progress with a permanent J-code assignment effective January 1, 2027, while the company reported $29.8 million in accounts receivable reflecting the commencement of commercial sales.
Company
VIRIDIAN THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology